This post is presented by our media partner Cannabis News Wire
View the original article here.
A recently released analysis has found a link between a history of cannabis usage and a decreased incidence of type 2 diabetes in adulthood. The analysis was done on seven studies, which include four cohorts and 11 surveys, by researchers at Iran’s Tabriz University of Medical Sciences. Compiling the findings, NORML stated that the four cohorts combined totaled more than 478,000 participants.
The comprehensive analysis revealed that the chances of developing type 2 diabetes in those who had been exposed to marijuana were diminished by a factor of 0.48 compared to those without any marijuana exposure.
The researchers highlighted that the act of consuming cannabis could potentially confer a safeguarding impact on the likelihood of type 2 diabetes development. However, they appended that due to the notable variation in findings across studies, it would be prudent to encourage investigations of heightened credibility, given the surge in marijuana consumption and legalization.
The researchers elaborated, saying “to the best of our knowledge, our analysis constitutes the most current body of evidence concerning the connection between T2DM and marijuana use,” as cited by NORML. They continued: “Given the increasing popularity of marijuana usage and the legalization thereof, there exists a growing imperative to design prospective, long-term, randomized studies that delve into the genuine ramifications of marijuana consumption and furnish pragmatic guidelines for its management.”
Commonly referred to as adult-onset diabetes and type 2 diabetes mellitus, type 2 diabetes is a chronic ailment characterized by elevated blood sugar levels. This form of diabetes is more prevalent than type 1, and, as Harvard Medical School states, although it typically manifests in middle and later life, it is progressively affecting younger demographics.
The Centers for Disease Control and Prevention (CDC) report that more than 37 million Americans have diabetes, with type 2 diabetes comprising 90% to 95% of these cases. The CDC further noted that “insulin, a hormone manufactured by the pancreas, functions akin to a key, enabling blood sugar to enter the body’s cells and be utilized as energy. However, in cases of type 2 diabetes, cells exhibit an abnormal response to insulin, a phenomenon known as insulin resistance.”
The CDC further clarified: “The pancreas compensates by generating more insulin in an attempt to provoke a cellular response. With time, the pancreas becomes overwhelmed, leading to escalated blood sugar levels, consequently setting the stage for prediabetes and eventually type 2 diabetes.”
In 2020, a study examined the potential of marijuana to reduce diabetes risk in individuals with hepatitis C. The study’s authors reported that “HCV infection heightens the risk of insulin resistance, consequently increasing susceptibility to diabetes. In the general populace, indications suggest that marijuana usage might offer protective effects against diabetes and related disorders.”
Furthermore, NORML highlighted that previous observational inquiries uncovered an inverse relationship between marijuana use and the odds of adult-onset diabetes and obesity. In clinical trial settings, it was revealed that administering THCV improved glycemic control in type 2 diabetes cases.
The researchers added that a placebo-controlled trial, documented in February, reported substantial enhancements in cholesterol and blood sugar levels among diabetic subjects who consumed plant-derived cannabinoid extracts via an eight-week regimen of two daily CBD sublingual spray doses.
There are other medicinal attributes of marijuana which companies such as IGC Pharma Inc. (NYSE American: IGC) are looking to leverage in order to come up with FDA-approved formulations aimed at treating several conditions, including chronic pain.
NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
This post was originally published by our media partner here.
